OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Fengcai Zhu, Chunlan Zhuang, Kai Chu, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 8, pp. 749-760
Open Access | Times Cited: 107
Fengcai Zhu, Chunlan Zhuang, Kai Chu, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 8, pp. 749-760
Open Access | Times Cited: 107
Showing 1-25 of 107 citing articles:
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Meera Madhavan, Adam Ritchie, Jeremy Aboagye, et al.
EBioMedicine (2022) Vol. 85, pp. 104298-104298
Open Access | Times Cited: 107
Meera Madhavan, Adam Ritchie, Jeremy Aboagye, et al.
EBioMedicine (2022) Vol. 85, pp. 104298-104298
Open Access | Times Cited: 107
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2
Junyu Chen, Pui Wang, Lunzhi Yuan, et al.
Science Bulletin (2022) Vol. 67, Iss. 13, pp. 1372-1387
Open Access | Times Cited: 100
Junyu Chen, Pui Wang, Lunzhi Yuan, et al.
Science Bulletin (2022) Vol. 67, Iss. 13, pp. 1372-1387
Open Access | Times Cited: 100
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 89
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 89
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Felicity Liew, Shubha Talwar, Andy Cross, et al.
EBioMedicine (2022) Vol. 87, pp. 104402-104402
Open Access | Times Cited: 88
Felicity Liew, Shubha Talwar, Andy Cross, et al.
EBioMedicine (2022) Vol. 87, pp. 104402-104402
Open Access | Times Cited: 88
Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
Shaofeng Deng, Hui Liang, Chen Pin, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1450-1450
Open Access | Times Cited: 68
Shaofeng Deng, Hui Liang, Chen Pin, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1450-1450
Open Access | Times Cited: 68
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
Devaki Pilapitiya, Adam K. Wheatley, Hyon‐Xhi Tan
EBioMedicine (2023) Vol. 92, pp. 104585-104585
Open Access | Times Cited: 48
Devaki Pilapitiya, Adam K. Wheatley, Hyon‐Xhi Tan
EBioMedicine (2023) Vol. 92, pp. 104585-104585
Open Access | Times Cited: 48
Vaccine Strategies to Elicit Mucosal Immunity
Yufeng Song, Frances Mehl, Steven L. Zeichner
Vaccines (2024) Vol. 12, Iss. 2, pp. 191-191
Open Access | Times Cited: 20
Yufeng Song, Frances Mehl, Steven L. Zeichner
Vaccines (2024) Vol. 12, Iss. 2, pp. 191-191
Open Access | Times Cited: 20
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
Chandramani Singh, Savita Verma, Prabhakar Reddy, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 37
Chandramani Singh, Savita Verma, Prabhakar Reddy, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 37
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Fengcai Zhu, Shoujie Huang, Xiaohui Liu, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1075-1088
Open Access | Times Cited: 33
Fengcai Zhu, Shoujie Huang, Xiaohui Liu, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1075-1088
Open Access | Times Cited: 33
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
Liang Zhang, Yao Jiang, Jinhang He, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
Liang Zhang, Yao Jiang, Jinhang He, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
Shaofeng Deng, Ying Liu, Rachel Chun-Yee Tam, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Shaofeng Deng, Ying Liu, Rachel Chun-Yee Tam, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Affinity Exploration of SARS-CoV-2 RBD Variants to mAb-Functionalized Plasmonic Metasurfaces for Label-Free Immunoassay Boosting
Fajun Li, Junping Hong, Chaoheng Guan, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 3383-3393
Closed Access | Times Cited: 26
Fajun Li, Junping Hong, Chaoheng Guan, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 3383-3393
Closed Access | Times Cited: 26
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
Xian Li, Mengxin Xu, Jingyi Yang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Xian Li, Mengxin Xu, Jingyi Yang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Potentials of saponins-based adjuvants for nasal vaccines
Kai Chen, Ning Wang, Xiaomin Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Kai Chen, Ning Wang, Xiaomin Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses
Divya Sinha, Melyssa Yaugel-Novoa, Louis Waeckel, et al.
Antiviral Research (2024) Vol. 223, pp. 105823-105823
Closed Access | Times Cited: 6
Divya Sinha, Melyssa Yaugel-Novoa, Louis Waeckel, et al.
Antiviral Research (2024) Vol. 223, pp. 105823-105823
Closed Access | Times Cited: 6
Mucosal vaccines for viral diseases: Status and prospects
Bingjie Ma, Mengxiao Tao, Zhili Li, et al.
Virology (2024) Vol. 593, pp. 110026-110026
Closed Access | Times Cited: 6
Bingjie Ma, Mengxiao Tao, Zhili Li, et al.
Virology (2024) Vol. 593, pp. 110026-110026
Closed Access | Times Cited: 6
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Ziyi Bai, Dandan Wan, Tianxia Lan, et al.
ACS Nano (2024) Vol. 18, Iss. 36, pp. 24650-24681
Open Access | Times Cited: 6
Ziyi Bai, Dandan Wan, Tianxia Lan, et al.
ACS Nano (2024) Vol. 18, Iss. 36, pp. 24650-24681
Open Access | Times Cited: 6
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity
Joshua Tobias, Peter Steinberger, Joy Wilkinson, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 795-795
Open Access | Times Cited: 5
Joshua Tobias, Peter Steinberger, Joy Wilkinson, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 795-795
Open Access | Times Cited: 5
COVID-19: The vaccine development strategies
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 645-667
Closed Access
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 645-667
Closed Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
